GTC
JANX icon

Ghost Tree Capital’s Janux Therapeutics JANX Stock Holding History

Ghost Tree Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$8.63M Buy
190,000
+140,000
+280% +$6.09M 2.61% 14
2024
Q2 		$2.09M Buy
+50,000
New +$2.35M 0.66% 42

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's JANX Position: Q3 2024 in Review

Ghost Tree Capital increased its Janux Therapeutics (JANX) stake by 280% in Q3 2024, buying an estimated $6.09M and bringing the position to 190,000 shares worth $8.63M. The position accounts for 2.61% of the portfolio, ranked #14.

Ghost Tree Capital first reported a position in JANX in Q2 2024 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold JANX as of Q3 2024.

  • Ghost Tree Capital held 190,000 shares of Janux Therapeutics worth $8.63M as of Q3 2024.
  • Ghost Tree Capital bought 140,000 Janux Therapeutics shares in Q3 2024, an estimated $6.09M.
  • Janux Therapeutics made up 2.61% of Ghost Tree Capital's portfolio in Q3 2024, its #14 holding.
  • Ghost Tree Capital first reported a position in Janux Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.